# US 2005/0032812 A1 · Compounds for the reduction of excessive food intake

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2005/0032812 A1
- Document ID: US20050032812A1
- Status: Published application
- Kind: A1
- Application number: 10/935,508
- Filed: 2004-09-07
- Published: 2005-02-10
- Earliest claimed: 2001-09-28
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Michael Pieper; Joachim Mierau
- Web page: https://patentgrep.com/patent/US20050032812A1

## CPC

- A61K 31/426: 1,3-Thiazoles
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 31/428: condensed with carbocyclic rings
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to the use of dopamine receptor agonists for preparing a pharmaceutical composition for the reduction of excessive food intake.

## Claims

### Claim 1

A method for treating overweight or obesity comprising administering a pharmaceutical composition comprising a dopamine receptor agonist selected from the group consisting of: D1, D2, D3, and D4 receptor agonists, such that food intake is reduced.

### Claim 2

A method for reducing food intake comprising administering a pharmaceutical composition comprising a dopamine receptor agonist selected from the group consisting of: D1, D2, D3, and D4 receptor agonists, such that food intake is reduced.

### Claim 3 (depends on 1)

The method of claim 1 wherein the obesity is obesity in type 2 diabetes.

### Claim 4 (depends on 1, 2)

The method of claims 1 or 2 wherein the pharmaceutical composition is administered continuously.

### Claim 5 (depends on 1, 2)

The method of claims 1 or 2 wherein the pharmaceutical composition is administered transdermally.

### Claim 6 (depends on 1)

The method of claim 1 wherein the dopamine receptor agonist is pramipexole or talipexole.

### Claim 7 (depends on 6)

The method of claim 6 wherein the dopamine receptor agonist is pramipexole.

### Claim 8 (depends on 6)

The method of claim 6 wherein the pramipexole or talipexole is administered in the form of an enantiomers.

### Claim 9 (depends on 6)

The method of claim 6 wherein the pramipexole or talipexole is administered in the form of a pharmacologically acceptable acid addition salts.

### Claim 10 (depends on 6)

The method of claim 6 wherein the pramipexole or talipexole is administered in the form of a hydrate.

### Claim 11 (depends on 6)

The method of claim 6 wherein the pramipexole or talipexole is administered in the form of a solvate.
